HR and breast cancer: Indeed, the addition of palbociclib, ribociclib, or abemaciclib to endocrine therapy in first or subsequent lines for patients with HR+/HER2- advanced breast cancer has demonstrated a clinically significant survival benefit, thus becoming a standard of care for this subset of patients [4,5,6,7,8,9].